Hyaluronic acid stimulates neutrophil function in vitro and in vivo. A review of experimental results and a presentation of a preliminary clinical trial.
Hyaluronic acid (HA) stimulates normal neutrophil function both in vitro and in vivo Stimulation was also achieved by subcutaneous administration of HA to patients with extreme susceptibility to bacterial infections. Clinical improvement of some patients was obtained in connection to the administration. It is premature at this time to conclude any therapeutic effect of HA in patients with extreme infection propensity. The data presented here, however, for certain merit further investigation on this matter.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy; D002056:Burns / Q000188:drug therapy; D002478:Cells, Cultured; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects
D006820:Hyaluronic Acid